Search

Your search keyword '"Reimer, Toralf"' showing total 563 results
Start Over Author "Reimer, Toralf"
563 results on '"Reimer, Toralf"'

153. Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer

Author

Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich, Nitz, Ulrike, Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich, and Nitz, Ulrike

Published
2017

154. Additional file 3: Table S3. of SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study

Author

Reimer, Toralf, Kempert, Sarah, Gerber, Bernd, Hans-Jürgen Thiesen, Hartmann, Steffi, and Koczan, Dirk

Abstract

List of non-evaluated 130 assays using TaqMan® OpenArray® PGx Panel due to the following reasons: 1…target revealed a constant of 100 % for one allele polymorphism (n = 89), 2…detected frequencies were not in Hardy-Weinberg equilibrium (n = 23), 3…incomplete or non-reproducible data sets (n = 17). *…assay C_11711720C_30 and assay C_11711720D_40 focused on the identical polymorphism (rs2032582). (DOCX 18 kb)

Published
2016
Full Text
View/download PDF

157. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial

Author

Forbes, John F, Sestak, Ivana, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael, Holcombe, Chris, Coleman, Robert E, Jones, Louise, Ellis, Ian, Cuzick, Jack, Sainsbury, Richard, Garber, Judy, Warwick, Jane, Buchanan, Mary, Buser, Katharina, Cawthorn, Simon, Coleman, Robert, Dowsett, Mitch, Eastell, Richard, Ejlertsen, Bent, Forbes, John, Kahan, Zsuzsanna, Baclesse, François, Mansel, Robert, Palva, Tiina, Rydén, Lisa, Stuart, Mary, Vaz, Fatima, Marsiglia, Hugo, Benyoucef, Ahmed, Berton-Rigaud, Dominique, Loustalot, Catherine, Serin, Daniel, Kerbrat, Pierre, Eymard, Jean-Christophe, Giard-Lefevre, Sylvia, Bonichon-Lamichhane, Nathalie, Monnier, Alain, Tubiana-Mathieu, Nicole, Piot, Gilles, de Lara, Christine Tunon, Bernard, Olivier, Simon-Swirski, Hélène, Gladieff, Laurence, Regaud, I Claudius, Fouchet-Goudier, Marie-Joseph, Dohollou, Nadine, Aquitaine, Nord, Elgard-Maitre, Anne-Marie, Bergerat, Jean-Pierre, Petit, Thierry, Marti, Adina, Toussaint, Caroline, Del Piano, Francesco, Ibrahim, Mahmoud, Fric, Danièle, Hönig, Arnd, Müller, Volkmar, Marmé, Frederik, Rautenberg, Beate, Schmidt, Marcus, Hanusch, Claus, Paepke, Stefan, Kaltenecker, Gabriele, Lemster, Sabine, Tio, Joke, Reimer, Toralf, Schnappauf, Benjamin, Baumann, Klaus, Schrader, Iris, Mundhenke, Christoph, Liedtke, Cornelia, Meinerz, Wolfgang, Thomssen, Christoph, Christl, Klaus, Hitschold, Thomas, Goerke, Kay, Kast, Karin, Runnebaum, Ingo, Lindner, Christoph, Scheidel, Peter, Herwig, Uwe, Bangemann, Nikola, Sommer, Harald, Göhring, Kornelia, Tulusan, Augustinus, Stauß, Eva, Köhler, Günter, Zahm, Dirk, Augustin, Doris, Hocke, Andrea, Neunhöffer, Tanja, Schmatloch, Sabine, Heinrich, Georg, Groß, Sabine, Breitbach, G P, Scharl, Anton, Klare, Peter, Stefek, Andrea, Hoffmann, Gerald, Martignoni, Franca, Weiss, Erich, Emons, Günter, Tesch, Hans-Christian, Beckmann, Matthias, Schmutzler, Rita, Schütte, Martin, Aktas, Bahriye, Hille-Betz, Ursula, Deryal, Mustafa, Dan Costa, Serban, Blümel, Beate, Göhring, Uwe-Jochen, Kleine-Tebbe, Anke, Schumacher, Claudia, Jasmin, Pourfard, Christoph, Uleer, Kullmer, Uwe, Krabisch, Petra, Gätje, Regine, Schwenzer, Thomas, Hindenburg, Hans-Joachim, Rempen, Andreas, Höffkes, Heinz-Gert, Stickeler, Elmar, Reffert, Christian, Seitz, Stephan, Splitt, Gerd, Böhne, Petra, Gnauert, Karsten, Strittmatter, Hans-Joachim, Baake, Gerold, Rezai, Mahdi, Noesselt, Thomas, Köhne, C-H, Hanf, Volker, Strumberg, Dirk, Dall, Peter, Schleicher, Peter, Schleicher, Bernd, Beldermann, Frank, Berghorn, Michael, Baerens, Dirk-Thoralf, Kolberg, Hans-Christian, Bauer, Lelia, Brucker, Cosima, Steck, Thomas, Boyle, Frances, Chaudhuri, Anupam, Wagga, Wagga, Moylan, Eugene, Donovan, Jenny, Della-Fiorentina, Stephen, Abdi, Ehtesham, Marx, Gavin, Beadle, Geoffrey, Donovan, Michael, Bennett, Ian, Gill, Peter Grantley, Baker, Caroline, Masters, Richard, Blum, Robert, Collins, John, Law, Michael, Hart, Stewart, Kannourakis, George, Snyder, Raymond, Joseph, David, McCrystal, Michael, Campbell, Ian, Jakesz, Raimund, Selim, Ursula, Singer, Christian, Heck, Dietmar, Greil, Richard, Ramoni, Angela, Bjelic-Radisic, Vesna, Reichenauer, Arno, Horvath, Wilfried, Thaler, Josef, Fridrik, Michael, Keckstein, Joerg, Jan, Lamote, L'Hermitte, Marc, Roelstrate, Heidi, Dirix, Luc, Bambust, Inneke, Seret, Monique, Liebens, Fabienne, Maerevoet, Maria, D'Hondt, Lionel, Berliere, Martine, Nogaret, Jean-Marie, Simon, Phillipe, O'Hanlon, Deirdre, Redmond, Henry Paul, Hill, Arnold, Evoy, Denis, Kerin, Michael, Gupta, Rajnish, Martin, Michael J, Fritis, Marcela, Schwartz, Ricardo, Yañez, Maria Loreto, Peralta, Octavio, Graiff, Claudio, Artioli, Fabrizio, Generali, Daniele, Orzalesi, Lorenzo, Visini, Marilena, Michiara, Maria, Pavesi, Lorenzo, Ravaioli, Alberto, Porpiglia, Mauro, Puglisi, Fabio, Pinotti, Graziella, Brincat, Stephen, Buser, Katharina S, Rabaglio, Manuela, Rauch, Daniel, Chappuis, Pierre O, Zaman, Khalil, Bucher, Susanne, Bolliger, Barbara, Pagani, Olivia, Falck, Anna-Karin, Kaij, Jakob, Margolin, Sara, Muslumanoglum, Mahmut, Bertelli, Gianfilippo, Bramley, Maria, Bristol, James, Chandrasekharan, Sankaran, Crellin, Perric, Daoud, Raouf, Dodwell, David, Drew, Philip, Dubey, Sidharth, Evans, Abigail, Ferguson, Douglas, Gendy, Raafat, Hamed, Hisham, Harding-McKean, Claudia, Horgan, Kieran, Iqbal, Shabana, Jibril, Jibril A, Kokan, Jalal, Kneeshaw, Peter, Lansdown, Mark, Lennard, Tom, Linforth, Rick, McIntosh, Stuart, Mitra, Sankha, Neades, Glyn, Ooi, Jane Louise, Patel, Ashraf, Rayter, Zenon, Reichert, Robert, Roberts, Fiona, Roche, Nicola, Rogers, Colin, Royle, Gavin, Shah, Elizabeth, Sibbering, Mark, Skene, Anthony Iain, Smith, Simon, Sparrow, Geoffrey, Thompson, Alastair, Vaidya, Jayant, Wolstenholme, Virginia, Wood, Jeremy, Yiangou, Constantinos, Zammit, Charles, Thornton, Rochelle, Probert, Flonda, Fong, Akiko, Francis, Nicole, Gili, Manuela, Eigenberger, Rosita, Supply, Daisy, Lefever, Inge, Muller, Bettina, Zlatar, Zdenka, Feer, Petra, Gkantiragas, Ioannis, Virkki, Marjo, Everhard, Sibille, Lemonnier, Jerome, Garcia, Sara, Ghanem, Saliha, Cole, Anna, O'Hare, Debra, Cronin, Elaine, Roche, Trudi, Kennedy, Emer, Ballot, Jo, Killilea, Niamh, Jennings, Marian, Lowry, Laura, Maxwell, Moira, Burke, Margaret, Gonzaga, Aliana Guerrieri, Bollani, Giorgia, Bianchetti, Andrea, Scalvini, Anna, Cretella, Elisabetta, Pasqualini, Antonella, Gobbi, Angela, Roselli, Jenny, Lagati, Angelita, Rapacchi, Elena, Lanza, Annalisa, Pini, Emanuela, Picardo, Elisa, Maggiorotto, Furio, Sottile, Roberta, Vallini, Ilaria, Cilia, Nadia, Patel, Mital, Bamford, Linda, Robertshaw, Helen, Inman, Hayle, Hill, Naomi, Dexter, Jane, Peasgood, Emily, Batty, Imogen, Cocks, Shirley, Mistry, Raksha, Sidders, Mary, Foulstone, Emily, Garlicka, Helen, Dawe, Catherine, Elliott, Jackie, Rooke, Kathy, Morris, Christine, Lester, Yvonne, Gibson, Sian, Chittock, Jill, Skelton, Amy, Gallimore, Elizabeth, Downes, Charlotte, Billett, Lynn, Caddy, Simone, Cumming, Helen, Cowell-Smith, Sharon, Turner, Caroline, Fernando, Sunjalee, Goodwin, Sarah, Taylor, Jo-Anne, Baines, Kizzy, Downer, Susan, Pilcher, Alice, Dobson, Tracey, Osborne, Lynn, Kuenzig, Greg, Hancock, Denise, Melia, Deborah, Gullaksen, Elaine, Hartup, Susan, Henson, Amy, Gibb, Jane, Coombs, Sarah, Taylor, Caroline, Kirkby, Amy, Thomas, Issy, Makinson, Karen, Kano, Yukie, Shah, Zoheb, Hardstaff, Lisa, Townley, Barbara, Hill, Philippa, McCurrie, Marilyn, Grassby, Sue, Henderson, Pamela, Talbot, Elizabeth, Bell, Ashley, Kanani, Reshma, Johnson, Joanne, Jones, Richard, Foster, Mel, Troke, Becky, Congdon, Hilary, Pascoe, Julie, Whelan, Sian, Edwards, Jenna, Brinkworth, Elaine, Blizard, Sheila, Clarke, Alison, Stevens, Kim, Harvey, Carol, Stacey, Jill, Mitchell, Sadie, Lowry, Tracey, Buckley, Sarah, Collins, Clare, Green, Liz, Jones, Helen, Conteh, Veronica, Ducket, Tracey, Kotze, Michelle, Strider, Paula, Stouraitis, Marina, Sundberg, Jan, Babiker, Abdel, Collins, Rory, Klijn, Jan, Ralston, Stuart, Tattersall, Martin, Weller, Ian, De Sousa, Andreia, Edwards, Rob, Ferguson, Sheila, Hickman, Jane, Johnson, Damian, Haidar, Nadia, Hammond, Victoria, Heighway, Emma, Ndoutoumou, Amalia, Sahota, Navdip, White, Laura, Aigret, Benoit, Batra, Priyanka, Knox, Jill, Oke, Adedayo, Ostler, Richard, and Sasieni, Peter

Subjects
Medicine (all), Medizin, skin and connective tissue diseases
Abstract

Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS.In a double-blind, multicentre, randomised placebo-controlled trial, we recruited women who had been diagnosed with locally excised, hormone-receptor-positive DCIS. Eligible women were randomly assigned in a 1:1 ratio by central computer allocation to receive 1 mg oral anastrozole or 20 mg oral tamoxifen every day for 5 years. Randomisation was stratified by major centre or hub and was done in blocks (six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation and only the trial statistician had access to treatment allocation. The primary endpoint was all recurrence, including recurrent DCIS and new contralateral tumours. All analyses were done on a modified intention-to-treat basis (in all women who were randomised and did not revoke consent for their data to be included) and proportional hazard models were used to compute hazard ratios and corresponding confidence intervals. This trial is registered at the ISRCTN registry, number ISRCTN37546358.Between March 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries and randomly assigned them to receive anastrozole (1449 analysed) or tamoxifen (1489 analysed). Median follow-up was 7·2 years (IQR 5·6-8·9), and 144 breast cancer recurrences were recorded. We noted no statistically significant difference in overall recurrence (67 recurrences for anastrozole vs 77 for tamoxifen; HR 0·89 [95% CI 0·64-1·23]). The non-inferiority of anastrozole was established (upper 95% CI

Published
2016

158. Additional file 1: Table S1. of SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study

Author

Reimer, Toralf, Kempert, Sarah, Gerber, Bernd, Hans-JĂźrgen Thiesen, Hartmann, Steffi, and Koczan, Dirk

Abstract

List of gene targets in the TaqManÂŽ OpenArrayÂŽ Pharmacogenomics (PGx) Panel (*source: www.PharmaADME.org). Phase I and II metabolism enzymes, responsible for the modification of functional groups and the conjugation with endogenous moieties respectively; transporters, responsible for the uptake and excretion of drugs in and out of cells. (DOCX 13 kb)

Published
2016
Full Text
View/download PDF

161. Eingeschränktes Axilla-Staging bei klinisch und sonografisch nodal-negativen Patientinnen mit frühem invasiven Mammakarzinom (c/iT1–2) im Rahmen der brusterhaltenden Therapie: erste Erkenntnisse nach Start der Intergroup-Sentinel-Mamma-(INSEMA-)Studie

Author

Reimer, Toralf, additional, Stachs, A., additional, Nekljudova, V., additional, Loibl, S., additional, Hartmann, S., additional, Wolter, K., additional, Hildebrandt, G., additional, and Gerber, B., additional

Published
2017
Full Text
View/download PDF

162. Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial.

Author

Mirza, Mansoor Raza, primary, Maenpaa, Johanna Unelma, additional, Braicu, Elena Ioana, additional, Vergote, Ignace, additional, Berton-Rigaud, Dominique, additional, Rosenberg, Per, additional, Huober, Jens Bodo, additional, Denys, Hannelore, additional, Joly Lobbedez, Florence, additional, Kristensen, Gunnar, additional, Reimer, Toralf, additional, Kridelka, Frederic, additional, Floquet, Anne, additional, Knudsen, Anja, additional, Aktas, Bahriye, additional, Baurain, Jean-Francois, additional, Follana, Philippe, additional, Juhler-Nøttrup, Trine, additional, Jederud, Christina, additional, and Sehouli, Jalid, additional

Published
2017
Full Text
View/download PDF

165. Distinct early proliferation response to neoadjuvant anti-HER2 antibody drug conjugate +/- endocrine therapy in early breast cancer in the WSG ADAPT HER2+/HR+ trial

Author

Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko, Krämer, Stefan, Braun, Michael, Schumacher, Claudia, Aktas, Bahriye, Forstbauer, Helmut, Reimer, Toralf, Fasching, Peter, Potenberg, Jochem, Hofmann, Daniel, Kates, Ronald E., Wuerstlein, Rachel, Christgen, Matthias, Kreipe, Hans, and Harbeck, Nadia

Subjects
Medizin
Published
2015

166. Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67) : Early outcome analysis from the prospective phase III WSG-PlanB trial

Author

Nitz, Ulrike, Gluz, Oleg, Kates, Ronald E., Hofmann, Daniel, Kreipe, Hans, Christgen, Matthias, Shak, Steve, Clemens, Michael, Kraemer, Stefan, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Kusche, Manfred, Heyl, Volker, Lorenz-Salehi, Fatemah, Just, Marianne, Liedtke, Cornelia, Wuerstlein, Rachel, and Harbeck, Nadia

Subjects
Medizin
Published
2015

167. Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.

Author

Degenhardt, Tom, Kreipe, Hans Heinrich, Gluz, Oleg, Kates, Ronald E., Liedtke, Cornelia, Kraemer, Stefan, Clemens, Michael R., Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Stefek, Andrea, Heyl, Volker, Wuerstlein, Rachel, Nitz, Ulrike, Harbeck, Nadia, Christgen, Matthias, Degenhardt, Tom, Kreipe, Hans Heinrich, Gluz, Oleg, Kates, Ronald E., Liedtke, Cornelia, Kraemer, Stefan, Clemens, Michael R., Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Stefek, Andrea, Heyl, Volker, Wuerstlein, Rachel, Nitz, Ulrike, Harbeck, Nadia, and Christgen, Matthias

Published
2016

168. Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.

Author

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Kraemer, Stefan, Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Liedtke, Cornelia, Svedman, Christer, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia, Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Kraemer, Stefan, Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Liedtke, Cornelia, Svedman, Christer, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans Heinrich, and Harbeck, Nadia

Published
2016

169. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Author

Gluz, Oleg, Nitz, Ulrike A., Christgen, Matthias, Kates, Ronald E., Shak, Steven, Clemens, Michael, Kraemer, Stefan, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Kusche, Manfred, Heyl, Volker, Lorenz-Salehi, Fatemeh, Just, Marianne, Hofmann, Daniel, Degenhardt, Tom, Liedtke, Cornelia, Svedman, Christer, Wuerstlein, Rachel, Kreipe, Hans H., Harbeck, Nadia, Gluz, Oleg, Nitz, Ulrike A., Christgen, Matthias, Kates, Ronald E., Shak, Steven, Clemens, Michael, Kraemer, Stefan, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Kusche, Manfred, Heyl, Volker, Lorenz-Salehi, Fatemeh, Just, Marianne, Hofmann, Daniel, Degenhardt, Tom, Liedtke, Cornelia, Svedman, Christer, Wuerstlein, Rachel, Kreipe, Hans H., and Harbeck, Nadia

Abstract

Purpose The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only a few prospective outcome results have been available so far. In the phase III PlanB trial, RS was prospectively used to define a subset of patients who received only endocrine therapy. We present 3-year outcome data and concordance analysis (among biomarkers/RS). Patients and Methods Central tumor bank was established prospectively from PlanB (intermediate and high-risk, locally human epidermal growth factor receptor 2-negative BC). After an early amendment, HR-positive, pN0-1 patients with RS <= 11 were recommended to omit chemotherapy. Results From 2009 to 2011, PlanB enrolled 3,198 patients with a median age of 56 years; 41.1% had node-positive and 32.5% grade 3 disease. In 348 patients (15.3%), chemotherapy was omitted based on RS <= 11. After 35 months median follow-up, 3-year disease-free survival in patients with RS <= 11 and endocrine therapy alone was 98% versus 92% and 98% in RS. 25 and RS 12 to 25 in chemotherapy-treated patients, respectively. Nodal status, central and local grade, the Ki-67 protein encoded by the MKI67 gene, estrogen receptor, progesterone receptor, tumor size, and RS were univariate prognostic factors for disease-free survival; only nodal status, both central and local grade, and RS were independent multivariate factors. Histologic grade was discordant between central and local laboratories in 44%. RS was positively but moderately correlated with the Ki-67 protein encoded by the MKI67 gene and grade and negatively correlated with progesterone receptor and estrogen receptor. Conclusion In this prospective trial, patients with enhanced clinical risk and omitted chemotherapy on the basis of RS <= 11 had excellent 3-year survival. The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potent

Published
2016

170. Levonorgestrel-releasing intrauterine devices

Author

Cohen, Ilan, Gerber, Bernd, Reimer, Toralf, Krause, Annette, Friese, Klaus, and Muller, Heiner

Subjects
Intrauterine contraceptives, Medicated -- Health aspects, Levonorgestrel -- Physiological aspects, Tamoxifen -- Adverse and side effects, Breast cancer -- Risk factors
Published
2001

171. Role ofTP53mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

Author

Darb-Esfahani, Silvia, primary, Denkert, Carsten, additional, Stenzinger, Albrecht, additional, Salat, Christoph, additional, Sinn, Bruno, additional, Schem, Christian, additional, Endris, Volker, additional, Klare, Peter, additional, Schmitt, Wolfgang, additional, Blohmer, Jens-Uwe, additional, Weichert, Wilko, additional, Möbs, Markus, additional, Tesch, Hans, additional, Kümmel, Sherko, additional, Sinn, Peter, additional, Jackisch, Christian, additional, Dietel, Manfred, additional, Reimer, Toralf, additional, Loi, Sherene, additional, Untch, Michael, additional, von Minckwitz, Gunter, additional, Nekljudova, Valentina, additional, and Loibl, Sibylle, additional

Published
2016
Full Text
View/download PDF

172. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Author

Gluz, Oleg, primary, Nitz, Ulrike A., additional, Christgen, Matthias, additional, Kates, Ronald E., additional, Shak, Steven, additional, Clemens, Michael, additional, Kraemer, Stefan, additional, Aktas, Bahriye, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Kusche, Manfred, additional, Heyl, Volker, additional, Lorenz-Salehi, Fatemeh, additional, Just, Marianne, additional, Hofmann, Daniel, additional, Degenhardt, Tom, additional, Liedtke, Cornelia, additional, Svedman, Christer, additional, Wuerstlein, Rachel, additional, Kreipe, Hans H., additional, and Harbeck, Nadia, additional

Published
2016
Full Text
View/download PDF

174. Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial.

Author

Degenhardt, Tom, primary, Kreipe, Hans Heinrich, additional, Gluz, Oleg, additional, Kates, Ronald E., additional, Liedtke, Cornelia, additional, Kraemer, Stefan, additional, Clemens, Michael R., additional, Nuding, Benno, additional, Reimer, Toralf, additional, Aktas, Bahriye, additional, Kummel, Sherko, additional, Just, Marianne, additional, Lorenz-Salehi, Fatemeh, additional, Uleer, Christoph, additional, Stefek, Andrea, additional, Heyl, Volker, additional, Wuerstlein, Rachel, additional, Nitz, Ulrike, additional, Harbeck, Nadia, additional, and Christgen, Matthias, additional

Published
2016
Full Text
View/download PDF

175. Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Author

Nitz, Ulrike, primary, Gluz, Oleg, additional, Christgen, Matthias, additional, Grischke, Eva-Maria, additional, Augustin, Doris, additional, Kümmel, Sherko, additional, Braun, Michael Wilhelm, additional, Potenberg, Jochem, additional, Kohls, Andreas, additional, Krauss, Katja, additional, Stefek, Andrea, additional, Schumacher, Claudia, additional, Forstbauer, Helmut, additional, Reimer, Toralf, additional, Fischer, Hans Holger, additional, Liedtke, Cornelia, additional, Wuerstlein, Rachel, additional, Kreipe, Hans Heinrich, additional, and Harbeck, Nadia, additional

Published
2016
Full Text
View/download PDF

176. Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.

Author

Kolben, Thomas, Jeschke, Udo, Reimer, Toralf, Karsten, Nora, Schmoeckel, Elisa, Semmlinger, Anna, Mahner, Sven, Harbeck, Nadia, and Kolben, Theresa M.

Subjects
BREAST cancer treatment, FAS proteins, INTERFERONS, APOPTOSIS, IMMUNOFLUORESCENCE
Abstract

Purpose: The Fas-antigen is a cell surface receptor that transduces apoptotic signals into cells. The purpose of this study was to evaluate FasL expression in breast cancer and to elucidate the role of its signaling in different breast cancer cell lines.Methods: T47D and MCF7 cells were used and cultured in Dulbecco’s modified Eagle’s medium. FasL translocation to the membrane was achieved by culturing the cells in the presence of human interferon-γ (IFNγ). Translocation was detected by immunofluorescence. The ability of a Fas:Fc fusion protein to trigger apoptosis in these cells was investigated by cell death detection ELISA. After incubation with IFNγ for 4 h and 18 h, apoptosis was assessed in response to treatment with Fas:Fc.Results: Immunofluorescence revealed that the used cell lines were positive for FasL which was increased and changed to more membrane-bound FasL expression after IFNγ stimulation. After stimulation with 50 IU/ml IFNγ, Fas:Fc significantly increased MCF7 apoptosis (1.39 ± 0.06-fold, p = 0.0004) after 18 h. After stimulation with 100 IU/ml, Fas:Fc significantly increased apoptosis both after 4 h (1.49 ± 0.15-fold, p = 0.018) and 18 h (1.30 ± 0.06-fold, p = 0.013). In T47D cells this effect was seen after 4 h of stimulation with 50 IU/ml and addition of Fas:Fc (1.6 ± 0.08-fold, p = 0.03).Conclusion: Membrane-bound FasL expression could be induced by IFNγ in a breast cancer cell model. More importantly, in the presence of IFNγ the Fas:Fc fusion protein was able to transmit pro-apoptotic signals to T47D and MCF7 cells, significantly inducing apoptosis. The current findings support further in vivo studies regarding FasL activation as a potential target for therapeutic intervention in breast cancer. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

177. Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive...

Author

Decker, Thomas, Brucker, Cosima, Engel, Anne, Fasching, Peter A., Göhler, Thomas, Jackisch, Christian, Janssen, Jan, Köhler, Andreas, Luedtke-Heckenkamp, Kerstin, Lüftner, Diana, van Mackelenbergh, Marion, Marmé, Frederik, Nusch, Arnd, Rautenberg, Beate, Reimer, Toralf, Schmidt, Marcus, Weide, Rudolf, Wimberger, Pauline, Roos, Christian, and Wöckel, Achim

Published
2023
Full Text
View/download PDF

178. Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.

Author

Turner, Nicholas C., Marmé, Frederik, Kim, Sung-Bae, Bonnefoi, Herve R., García-Sáenz, José A., Torres, Antonio A., Bear, Harry Douglas, Tesch, Hans, Melé Olivé, Mireia, Mc Carthy, Nicole, Cruz Jurado, Josefina, Im, Seock-Ah, Liu, Yuan, Zhang, Zhe, Weber, Karsten Ernst, Felder, Bärbel, Nekljudova, Valentina, Reimer, Toralf, Denkert, Carsten, and Loibl, Sibylle

Published
2023
Full Text
View/download PDF

179. Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis

Author

Röwer, Claudia, Ziems, Björn, Radtke, Anngret, Schmitt, Oliver, Reimer, Toralf, Koy, Cornelia, Thiesen, Hans-Jürgen, Gerber, Bernd, and Glocker, Michael O

Subjects
Adult, Aged, 80 and over, Proteomics, Paraffin Embedding, Carcinoma, Ductal, Breast, Pyruvate Kinase, Glyceraldehyde-3-Phosphate Dehydrogenases, Nuclear Proteins, Breast Neoplasms, Middle Aged, Immunohistochemistry, Young Adult, Nucleoside-Diphosphate Kinase, Biomarkers, Tumor, Image Processing, Computer-Assisted, Humans, Intercellular Signaling Peptides and Proteins, Original Article, Female, Breast, Nucleophosmin, Algorithms, Aged
Abstract

Due to enormous advances in quantitative proteomics and in immunohistochemistry (pathology), the two research areas have now reached the state to be successfully interwoven in order to tackle challenges in toponostics and to open tumor-targeted systems pathology approaches. In this study the differential expressions of candidate proteins nucleophosmin, nucleoside diphosphate kinase A/B (NDKA/B), osteoinducive factor (mimecan), and pyru-vate kinase M2 from a quantitative proteome signature for invasive ductal breast cancer were determined by immunohistochemistry on 53 tissue slices from formalin-fixed and paraffin-embedded tumor and control tissue samples from ten patients and fourteen controls. In addition, 87 images from the Human Protein Atlas representing seven tumor and nine normal breast tissue samples were investigated by computer-assisted semi-quantitative density measurements on nucleophosmin, nucleoside diphosphate kinase A/B (NDKA/B), osteoinducive factor (mimecan), pyruvate kinase M2, glyceraldehyde-3-phosphate dehydro-genase (GAP-DH), and mimecan (osteoinductive factor). Both IHC data sets match well to each other and support the quantitative proteome analysis data. Determining spatial distribution of signature protein expressions by protein imaging on morphologically intact tissue samples at the sub-cellular level and, hence, keeping all topological information, presents an added value to quantitative proteome data. Such comprehensive data sets are needed for both, pathway analyses and for "next generation clinical diagnostics" approaches.

Published
2011

180. Abstract S3-04: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer

Author

von Minckwitz, Gunter, primary, Reimer, Toralf, additional, Potenberg, Jochen, additional, Conrad, Bettina, additional, Schürer, Ulrike, additional, Eidtmann, Holger, additional, Just, Marianne, additional, Paepke, Stefan, additional, Stickeler, Elmar, additional, Heinrich, Georg, additional, Untch, Michael, additional, Moebus, Volker, additional, Thomssen, Christoph, additional, Jackisch, Christian, additional, Huober, Jens, additional, Loibl, Sibylle, additional, Nekljudova, Valentina, additional, and Nitz, Ulrike, additional

Published
2015
Full Text
View/download PDF

181. Abstract P4-15-01: Distinct early proliferation response to neoadjuvant anti-HER2 antibody drug conjugate +/- endocrine therapy in early breast cancer in the WSG ADAPT HER2+/HR+ trial

Author

Gluz, Oleg, primary, Nitz, Ulrike, additional, Sherko, Kuemmel, additional, Stefan, Kraemer, additional, Braun, Michael, additional, Schumacher, Claudia, additional, Aktas, Bahriye, additional, Forstbauer, Helmut, additional, Reimer, Toralf, additional, Fasching, Peter, additional, Potenberg, Jochem, additional, Hofmann, Daniel, additional, Kates, Ronald E, additional, Wuerstlein, Rachel, additional, Christgen, Matthias, additional, Kreipe, Hans H, additional, and Harbeck, Nadia, additional

Published
2015
Full Text
View/download PDF

182. Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

Author

Nitz, Ulrike, primary, Gluz, Oleg, additional, Kates, Ronald E, additional, Hofmann, Daniel, additional, Kreipe, Hans H, additional, Christgen, Matthias, additional, Shak, Steve, additional, Clemens, Michael, additional, Kraemer, Stefan, additional, Aktas, Bahriye, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Kusche, Manfred, additional, Heyl, Volker, additional, Lorenz-Salehi, Fatemah, additional, Just, Marianne, additional, Liedtke, Cornelia, additional, Wuerstlein, Rachel, additional, and Harbeck, Nadia, additional

Published
2015
Full Text
View/download PDF

184. Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Author

Denkert, Carsten, primary, von Minckwitz, Gunter, additional, Brase, Jan C., additional, Sinn, Bruno V., additional, Gade, Stephan, additional, Kronenwett, Ralf, additional, Pfitzner, Berit M., additional, Salat, Christoph, additional, Loi, Sherene, additional, Schmitt, Wolfgang D., additional, Schem, Christian, additional, Fisch, Karin, additional, Darb-Esfahani, Silvia, additional, Mehta, Keyur, additional, Sotiriou, Christos, additional, Wienert, Stephan, additional, Klare, Peter, additional, André, Fabrice, additional, Klauschen, Frederick, additional, Blohmer, Jens-Uwe, additional, Krappmann, Kristin, additional, Schmidt, Marcus, additional, Tesch, Hans, additional, Kümmel, Sherko, additional, Sinn, Peter, additional, Jackisch, Christian, additional, Dietel, Manfred, additional, Reimer, Toralf, additional, Untch, Michael, additional, and Loibl, Sibylle, additional

Published
2015
Full Text
View/download PDF

186. Acute-phase proteins in prediction of preeclampsia in patients with abnormal midtrimester uterine Doppler velocimetry.

Author

Stubert, Johannes, Kleber, Torsten, Bolz, Michael, Külz, Thomas, Dieterich, Max, Richter, Dagmar-Ulrike, and Reimer, Toralf

Subjects
UTERUS abnormalities, PREECLAMPSIA diagnosis, DOPPLER velocimetry, ACUTE phase proteins, PROGRANULIN, RECEIVER operating characteristic curves
Abstract

Aims: Manifestation of preeclampsia is characterized by an inflammatory response and altered expression of acute-phase proteins. In this study, we examined the predictive value of serum amyloid A, progranulin, transthyretin, C-reactive protein and interleukin-6. Soluble endoglin was used as control. Methods: Maternal serum levels of the putative biomarkers were measured in 49 women with a midtrimester bilateral abnormal uterine artery Doppler velocimetry. Results: Preeclampsia developed in 26.5 %. 75.0 % had an early-onset disease (<34 + 0 weeks). Delivery <34 + 0 weeks was indicated in 16.3 %. 12.2 % of patients developed a normotensive intrauterine growth restriction. All of the putative biomarkers were not predictive for preeclampsia. But serum levels of progranulin and also of soluble endoglin were increased in cases with development of a severe normotensive intrauterine growth restriction. Only soluble endoglin was predictive for the development of preeclampsia with an area under curve in the receiver operating curve analysis of 0.761 ( P = 0.006). Using a cut-off level of ≥9.14 ng/mL, sensitivity, specificity, positive predictive value and negative predictive value were 53.9, 88.9, 63.6 and 84.2 %, respectively. Conclusions: Inflammation is a late event during development of preeclampsia, and acute-phase proteins are not predictive for the disease in a high-risk population without clinical symptoms during the second trimester. Progranulin is a putative new biomarker for an early detection of intrauterine growth restriction in women without concomitant hypertensive disorders. Soluble endoglin improved predictive values for preeclampsia in patients with abnormal uterine Doppler. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

193. Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer

Author

Ruckhäberle, Eugen, primary, Karn, Thomas, additional, Denkert, Carsten, additional, Loibl, Sibylle, additional, Ataseven, Beyhan, additional, Reimer, Toralf, additional, Becker, Sven, additional, Holtrich, Uwe, additional, Rody, Achim, additional, Darb-Esfahani, Silvia, additional, Nekljudova, Valentina, additional, and von Minckwitz, Gunter, additional

Published
2013
Full Text
View/download PDF

195. Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie

Author

Emons, Günter, primary, Günthert, Andreas, additional, Thiel, Falk C., additional, Camara, Oumar, additional, Strauss, Hans-Georg, additional, Breitbach, Georg-Peter, additional, Kölbl, Heinz, additional, Reimer, Toralf, additional, Finas, Dominique, additional, and Rensing, Klaus, additional

Published
2013
Full Text
View/download PDF

198. A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy.

Author

Pietzner, Klaus, primary, Chekerov, Radoslav, additional, Reinthaller, Alexander, additional, Reimer, Daniel, additional, Reimer, Toralf, additional, Angleitner-Boubenizek, Lukas, additional, Tschirschmann, Miriam, additional, Lindhofer, Horst, additional, Braicu, Elena Ioana, additional, Fotopoulou, Christina, additional, and Sehouli, Jalid, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results